Lars Franksson

1.3k total citations
23 papers, 1.1k citations indexed

About

Lars Franksson is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Lars Franksson has authored 23 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Immunology, 5 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in Lars Franksson's work include Immune Cell Function and Interaction (19 papers), T-cell and B-cell Immunology (15 papers) and Immunotherapy and Immune Responses (12 papers). Lars Franksson is often cited by papers focused on Immune Cell Function and Interaction (19 papers), T-cell and B-cell Immunology (15 papers) and Immunotherapy and Immune Responses (12 papers). Lars Franksson collaborates with scholars based in Sweden, Germany and India. Lars Franksson's co-authors include Klas Kärre, Claes Öhlén, Petter Höglund, K Kärre, Hans‐Gustaf Ljunggren, Rickard Glas, Beverly H. Koller, Ennio Carbone, Max Petersson and Rolf Kiessling and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and The Journal of Immunology.

In The Last Decade

Lars Franksson

23 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lars Franksson Sweden	18	975	205	124	75	70	23	1.1k
Franca Spada United States	10	1.3k 1.3×	244 1.2×	103 0.8×	120 1.6×	43 0.6×	12	1.4k
L D Barber United States	15	649 0.7×	87 0.4×	110 0.9×	62 0.8×	106 1.5×	25	766
M M Tutt United States	10	821 0.8×	169 0.8×	117 0.9×	72 1.0×	84 1.2×	10	924
Angela Weiss United States	9	1.1k 1.1×	264 1.3×	187 1.5×	75 1.0×	83 1.2×	12	1.2k
C E Yockey United States	6	714 0.7×	169 0.8×	124 1.0×	110 1.5×	24 0.3×	8	883
Ralph M. Steinman United States	7	592 0.6×	118 0.6×	178 1.4×	35 0.5×	35 0.5×	7	690
H. Robson MacDonald Switzerland	16	941 1.0×	225 1.1×	150 1.2×	54 0.7×	29 0.4×	30	1.1k
E Braakman Netherlands	7	456 0.5×	144 0.7×	115 0.9×	53 0.7×	47 0.7×	15	597
J Minowada Japan	9	513 0.5×	89 0.4×	123 1.0×	36 0.5×	49 0.7×	19	717
Mahboob Salim United Kingdom	12	868 0.9×	305 1.5×	164 1.3×	110 1.5×	39 0.6×	14	1.0k

Countries citing papers authored by Lars Franksson

Since Specialization

Citations

This map shows the geographic impact of Lars Franksson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Franksson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Franksson more than expected).

Fields of papers citing papers by Lars Franksson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Franksson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Franksson. The network helps show where Lars Franksson may publish in the future.

Co-authorship network of co-authors of Lars Franksson

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Franksson. A scholar is included among the top collaborators of Lars Franksson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Franksson. Lars Franksson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tell, Roger, Christer Sederholm, Claes Klintenberg, et al.. (2009). Multicentre phase II trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer.. PubMed. 28(5B). 2851–7. 7 indexed citations

Persson, Ulf, Sixten Borg, Tor Ekman, et al.. (2005). Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: Comparative analysis of drug utilization, costs, and hematologic response. Advances in Therapy. 22(3). 208–224. 12 indexed citations

Sandberg, Johan K., Lars Franksson, Jonas Sundbäck, et al.. (2000). T Cell Tolerance Based on Avidity Thresholds Rather Than Complete Deletion Allows Maintenance of Maximal Repertoire Diversity. The Journal of Immunology. 165(1). 25–33. 63 indexed citations

Glas, Rickard, Lars Franksson, Clas Une, et al.. (2000). Recruitment and Activation of Natural Killer (Nk) Cells in Vivo Determined by the Target Cell Phenotype. The Journal of Experimental Medicine. 191(1). 129–138. 123 indexed citations

Franksson, Lars, et al.. (1999). Peptide dependency and selectivity of the NK cell inhibitory receptor Ly-49C. European Journal of Immunology. 29(9). 2748–2758. 55 indexed citations

Höglund, Petter, Rickard Glas, Carine Ménard, et al.. (1998). β2 -Microglobulin-deficient NK cells show increased sensitivity to MHC class I-mediated inhibition, but self tolerance does not depend upon target cell expression of H-2Kb and Db heavy chains. European Journal of Immunology. 28(1). 370–378. 44 indexed citations

Sandberg, Johan K., Per Grufman, Elisabeth Z. Wolpert, et al.. (1998). Superdominance Among Immunodominant H-2Kb-Restricted Epitopes and Reversal by Dendritic Cell-Mediated Antigen Delivery. The Journal of Immunology. 160(7). 3163–3169. 46 indexed citations

Carbone, Ennio, Giuseppe Terrazzano, Marco Colonna, et al.. (1996). Natural killer clones recognize specific soluble HLA class I molecules. European Journal of Immunology. 26(3). 683–689. 38 indexed citations

Zhou, Xianzheng, et al.. (1995). Characterization of TAP‐Independent and Brefeldin A‐Resistant Presentation of Sendai Virus Antigen to CD8⁺ Cytotoxic T Lymphocytes. Scandinavian Journal of Immunology. 42(1). 66–75. 20 indexed citations

10.

Wolpert, Elisabeth Z., Lars Franksson, & Klas Kärre. (1995). Dominant and cryptic antigens in the MHC class I restricted T cell response across a complex minor histocompatibility barrier: analysis and mapping by elution of cellular peptides. International Immunology. 7(6). 919–928. 32 indexed citations

11.

Salazar‐Onfray, Flavio, Max Petersson, Lars Franksson, et al.. (1995). IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression.. The Journal of Immunology. 154(12). 6291–6298. 64 indexed citations

12.

Carbone, Ennio, György Stuber, Lars Franksson, et al.. (1993). Reduced expression of major histocompatibility complex class I free heavy chains and enhanced sensitivity to natural killer cells after incubation of human lymphoid lines with β₂‐microglobulin. European Journal of Immunology. 23(8). 1752–1756. 29 indexed citations

13.

Franksson, Lars, et al.. (1993). Tumorigenicity conferred to lymphoma mutant by major histocompatibility complex-encoded transporter gene.. The Journal of Experimental Medicine. 177(1). 201–205. 52 indexed citations

14.

Franksson, Lars, Max Petersson, Rolf Kiessling, & Klas Kärre. (1993). Immunization against tumor and minor histocompatibility antigens by eluted cellular peptides loaded on antigen processing defective cells. European Journal of Immunology. 23(10). 2606–2613. 33 indexed citations

15.

Franksson, Lars, et al.. (1993). Identification of H‐2K^b‐, D^b‐ and D^d‐binding peptides derived from amino acid sequences of polyoma virus T antigens. International Journal of Cancer. 54(6). 992–995. 5 indexed citations

16.

Stuber, György, Susanne Modrow, Petter Höglund, et al.. (1992). Assessment of major histocompatibility complex class I interaction with Epstein‐Barr virus and human immunodeficiency virus peptides by elevation of membrane H‐2 and HLA in peptide loading‐deficient cells. European Journal of Immunology. 22(10). 2697–2703. 51 indexed citations

17.

Öhlén, Claes, et al.. (1991). The RMA-S lymphoma mutant; consequences of a peptide loading defect on immunological recognition and graft rejection. International Journal of Cancer. 47(S6). 38–44. 35 indexed citations

18.

Aosai, Fumie, Claes Öhlén, Hans‐Gustaf Ljunggren, et al.. (1991). Different types of allospecific CTL clones identified by their ability to recognize peptide loading‐defective target cells. European Journal of Immunology. 21(11). 2767–2774. 55 indexed citations

19.

Höglund, Petter, Claes Öhlén, Ennio Carbone, et al.. (1991). Recognition of beta 2-microglobulin-negative (beta 2m-) T-cell blasts by natural killer cells from normal but not from beta 2m- mice: nonresponsiveness controlled by beta 2m- bone marrow in chimeric mice.. Proceedings of the National Academy of Sciences. 88(22). 10332–10336. 220 indexed citations

20.

Öhlén, Claes, Maria Teresa Bejarano, Alvar Grönberg, et al.. (1989). Studies of sublines selected for loss of HLA expression from an EBV-transformed lymphoblastoid cell line. Changes in sensitivity to cytotoxic T cells activated by allostimulation and natural killer cells activated by IFN or IL-2.. The Journal of Immunology. 142(9). 3336–3341. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact